Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens

doi:10.3748/wjg.v30.i44.4725

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1091)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

HTML

665

Figures (1-6)

Tables (1-3)

Sum=805

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

106

Sum=157

Publishing Process of This Article

Item

Count

Browse

Download

Sum=90

Nov 28, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Nov 28, 2024; 30(44): 4725-4737
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4725

Full Size Figure Download Figure

Figure 2 Dynamic changes in hepatitis B surface antibody levels in the HBsAg seroconversion and non-seroconversion groups during 48 weeks of follow-up. ^aP < 0.001. HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody.

Citation: Lu R, Zhang M, Liu ZH, Hao M, Tian Y, Li M, Wu FP, Wang WJ, Shi JJ, Zhang X, Jia XL, Jiang ZC, Li XM, Xu GH, Li YP, Dang SS. Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. World J Gastroenterol 2024; 30(44): 4725-4737
URL: https://www.wjgnet.com/1007-9327/full/v30/i44/4725.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i44.4725